Using tumor DNA to adjust treatment in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests if checking your blood for tumor DNA after two rounds of chemotherapy can help doctors decide if they can safely lower the dose or switch your treatment. It's for people with advanced colorectal cancer that started on the left side or in the rectum.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be on the left side of your colon or in your rectum.
- You must not have had chemotherapy for cancer that has spread (metastatic) before.
- Your tumor must not have a BRAF V600E mutation and must be microsatellite stable (MSS).
- You must have at least one measurable tumor on scans.
- You must be in generally good health (ECOG score 0 or 1) with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
This study uses a blood test called ctDNA to help tailor (personalize) neoadjuvant chemotherapy for people with colorectal or appendix cancer before surgery. The goal is to see if using ctDNA can help doctors pick the most appropriate chemotherapy plan for you.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This study looks at whether a simple blood test can help doctors decide if you should receive a specific type of cancer drug again. The blood test looks for cancer DNA to predict if the drug will work for your advanced colorectal cancer.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
Hear when a new Metastatic Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.